Wednesday, May 24, 2017| American Society of Cataract & Ref Surgeons, ASCRS, Business

EyewireTV — Eye Care Executives Discuss the Future of Ophthalmology

In this week’s EyewireTV, executives at the Ophthalmology Innovation Summit in Los Angeles provide EyewireTV updates on their company’s products and pipeline.

Watch Video

Wednesday, May 17, 2017| Dry Eye, Fluoroquinolones, Nidek, Retinal detachment, RD

EyewireTV — New Dry Eye Guidance; Fluoroquinolones/Retinal Detachment Link

In this week’s EyewireTV, the Tear Film & Ocular Surface Society (TFOS) presents the conclusions and recommendations of the TFOS Dry Eye Workshop II (DEWS II), which may have an impact on the way dry eye disease is diagnosed and examined; and new FDA communication indicates there is no firm evidence suggesting that fluoroquinolone antibiotics may lead to retinal detachment. Also, Nidek launches the SL-2000 Slit Lamp, which aims to provide a clear view of ocular tissue in nearly natural color.

Watch Video

Wednesday, May 10, 2017

EyewireTV - Breaking Industry News from the ASCRS Meeting in Los Angeles

In this week’s EyewireTV, Bausch + Lomb introduces the Stellaris Elite vision enhancement system and Vitesse open-port vitrectomy system; and Zeiss fully integrates the latest generation of Barrett IOL power calculation formulas into the IOLMaster 700. Also, Alcon launches two new cataract surgical technologies—the Intrepid Transformer I/A Handpiece and LenSx Laser SoftFit Patient Interface options.

Watch Video

Wednesday, May 03, 2017| AngioVue OCTA system, Clinical Trials, Dry Eye, Inflammation, Kala Pharmaceuticals, optical coherence tomography angiography, OCT angiography, Optovue, Parion Sciences, Shire

EyewireTV - New OCTA Imaging; Shire Acquires Rights to DED Drug Candidate

In this week’s EyewireTV, Optovue releases the AngioVueHD, an update to the AngioVue system that allows for higher-density OCT angiography imaging; and Kala Pharmaceuticals announces positive topline results from its phase 3 clinical trial of KPI-121 1% for postoperative inflammation and pain. Also, Shire and Parion Sciences enter into an agreement granting Shire exclusive global rights to develop and commercialize dry eye disease drug candidate P-321.

Watch Video

Wednesday, April 26, 2017| Allergan, Clinical Trials, Diabetic Retinopathy, FDA Approval/Clearance, Hydrus™ Microstent, Ivantis, Technology

EyewireTV — FDA Clears TrueTear Neurostimulator; IBM Technology Detects DR

In this week’s EyewireTV, Allergan receives marketing authorization from the FDA for the TrueTear Intranasal Tear Neurostimulator, developed to temporarily increase tear production during neurostimulation in adult patients; and IBM releases the results of new research using deep learning and visual analytics technology to advance early detection of diabetic retinopathy. Also, Ivantis receives FDA clearance to initiate a second investigational device exemption clinical trial of the Hydrus Microstent.

Watch Video

Wednesday, April 19, 2017| Aberrometry, Aerie Pharmaceuticals, Clinical Trials, Diabetic macular edema, DME, Diabetic Retinopathy, Excimer Lasers, FDA Approval/Clearance, Glaucoma, Lucentis, Nidek, Ranibizumab

EyewireTV — New Lucentis Approval; Nidek Launches Excimer Laser System

In this week’s EyewireTV, Lucentis (ranibizumab) receives FDA approval for the treatment of diabetic retinopathy in people with or without diabetic macular edema; and Nidek launches the NAVEX Quest M2 Nidek Advanced Vision Excimer Laser System, which incorporates the Quest M2 excimer laser system, the OPD-Scan III aberrometer and corneal topographer, and Final Fit software. Also, Aerie Pharmaceuticals reports 6-month topline safety and efficacy results of its phase 3 clinical trial (Rocket 4) for glaucoma product candidate Rhopressa.

Watch Video

Tuesday, April 11, 2017| Bausch+Lomb, Dry Eye, FDA Approval/Clearance, Imprimis Pharmaceuticals, Phacoemulsification, Stellaris Vision Enhancement System

EyewireTV — FDA Outpaces Europe in Drug Approvals; New Phaco Platform

In this week’s EyewireTV, a study published online in the New England Journal of Medicine reveals that the FDA outpaced the European Medicines Agency in review times and approval of new drugs between 2011 and 2015; and Bausch + Lomb receives FDA 510(k) clearance for the Stellaris Elite vision enhancement system, the company’s next-generation phaco platform. Also, Imprimis Pharmaceuticals enters into a licensing agreement for the exclusive worldwide rights to Klarity, a patented ophthalmic topical solution and gel technology for patients with dry eye disease.

Watch Video

Wednesday, April 05, 2017| , Cataracts

EyewireTV - Ocular Melanoma Trial; Hepatitis C Link to Cataracts

In this week’s EyewireTV, the first cases using a new drug candidate (AU-011; Aura Biosciences) for treating ocular melanoma are performed at Wills Eye Hospital in Philadelphia; the National Eye Institute outlines its Audacious Goals Initiative, which provides recommendations for regenerating retinal ganglion cells. Also, a large population-based study suggests hepatitis C infection may increase the risk of cataracts.

Watch Video

Wednesday, March 29, 2017| AcrySof® IQ ReSTOR Multifocal IOL, Alcon, Allergan, Astigmatism, FDA Approval/Clearance, Intraocular Pressure, IOP, Presbyopia

EyewireTV — New Multifocal Toric IOL; Restasis Multidose Now Available

In this week’s EyewireTV, the FDA approves Alcon’s Acrysof ReSTOR 2.5 D Multifocal Toric IOL with Activefocus, designed to address astigmatism and presbyopia at the same time; and Allergan announces the availability of Restasis Multidose, the first and only FDA-approved preservative-free, prescription eye drop in the United States to be available in a multidose bottle. Also, the Icare HOME tonometer, which allows for 24-hour self-measuring of IOP, receives FDA clearance.

Watch Video

Wednesday, March 22, 2017| dry age-related macular degeneration, dry AMD, Glaucoma, Glaukos Corporation, Intraocular Pressure, IOP, Microinvasive Glaucoma Surgery (MIGS), Minimally Invasive Micro Sclerostomy (MIMS) , stem cell therapy

EyewireTV — Unregulated Stem Cell Procedures; New Glaucoma Device

In this week’s EyewireTV, the New England Journal of Medicine details an alarming case in which three women with dry AMD suffered severe, permanent eye damage after stem cells were injected into their eyes in an unproven treatment at a clinic in Florida; and Israel-based Sanoculis receives the CE Mark for its minimally invasive micro sclerostomy (MIMS) device for the reduction of IOP in glaucoma patients. Also, the American Medical Association grants Glaukos 5-year extensions to three Category III CPT codes that detail Medicare reimbursements for current and future microinvasive glaucoma surgery (MIGS) devices.

Watch Video

Wednesday, March 08, 2017| FDA Approval/Clearance, Glaucoma, IOL Calculations, IRIDEX, Topcon Medical Systems

EyewireTV — Republicans Aim to Replace Obamacare; Aladdin Biometer FDA Clearance

In this week’s EyewireTV, House Republicans unveil legislation called the American Health Care Act, which aims to repeal and replace the Affordable Care Act; and Topcon Medical Systems receives FDA clearance for the Aladdin Biometer with Corneal Topographer HW3.0, a device designed to save time and add accuracy to IOL calculation measurements. Also, Iridex announces the availability of the G-Probe Illuminate, a new FDA-cleared probe for use with the CYCLO G6 Glaucoma Laser System.

Watch Video

Thursday, March 02, 2017| Abbott Medical Optics, AMO, Acquisitions, Mergers, Bausch+Lomb, Carl Zeiss Meditec, FDA Approval/Clearance, Glaucoma, Johnson & Johnson Vision Care, Myopia, Nicox , ReLEx SMILE, VisuMax femtosecond laser

EyewireTV — J&J Completes AMO Acquisition; SMILE Procedure Commercially Available in US

In this week’s EyewireTV, Johnson & Johnson completes its $4.3 billion acquisition of Abbott Medical Optics. The combined company will operate under the brand name Johnson & Johnson Vision; and Carl Zeiss Meditec receives FDA approval of a PMA supplement for software changes to the VisuMax femtosecond laser, allowing surgeons in the US to perform the ReLEx SMILE procedure for the correction of myopia. Also, Bausch + Lomb and Nicox resubmit a new drug application to the FDA for glaucoma candidate latanoprostene bunod (0.024%).

Watch Video

Wednesday, February 22, 2017| Blindness, Dry Eye, Eyegate Pharmaceuticals, Inflammation, Shire, Valeant

EyewireTV — Early Xiidra Sales; Valeant Boosts Ophthalmic Portfolio

In this week’s EyewireTV, Shire releases information about the early sales of its dry eye disease drug Xiidra (lifitegrast); and Valeant acquires the global commercial and manufacturing rights to EyeGate Pharmaceuticals’ EyeGate II Delivery System and EGP-437 combination product for postoperative pain and inflammation. Also, the Himalayan Cataract Project, a major eye care initiative to develop sustainable solutions for blindness throughout Asia and Africa, is one of eight finalists in a $100 million global competition.

Watch Video

Wednesday, February 15, 2017| FDA Approval/Clearance, Lions Eye Institute, Lucentis

EyewireTV — Lucentis Launches Prefilled Syringe; LEITR Doubles in Size

In this week’s EyewireTV, Lucentis (ranibizumab) is now available in the United States in a new 0.5-mg prefilled syringe; and the Lions Eye Institute for Transplant & Research has doubled its size after acquiring International Sight Restoration, the largest eye bank for international ocular distribution. Also, three companies with early-stage products for serious ocular conditions (Aura Biosciences, Regenxbio, and GenSight Biologics) receive the green light from the FDA to proceed with clinical development.

Watch Video

Wednesday, February 08, 2017| Glaucoma

EyewireTV — World’s Top Glaucoma Specialists Discuss Future Treatment Options

In this week’s EyewireTV, leading glaucoma specialists, investors, and industry executives gather at the Glaucoma 360 meeting in San Francisco to exchange ideas and provide updates on new developments in glaucoma. Several attendees talk to EyewireTV about which technologies or treatment options—either already available or in clinical development—they believe will have a major impact on the way glaucoma patients are treated.

Watch Video
Load More